5-(2-chloro-4-nitrophenyl)-1,3-oxazole | 198821-75-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(2-chloro-4-nitrophenyl)-1,3-oxazole
• 英文别名: 5-(2-chloro-4-nitrophenyl)oxazole；3-methoxy-4-(1,3-oxazol-5-yl)aniline；5-(2-Chloro-4-nitrophenyl)-oxazole
• CAS: 198821-75-9
• 化学式: C₉H₅ClN₂O₃
• 分子量: 224.603
• InChiKey: TVYQUZVNFBSCGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(2-chloro-4-nitrophenyl)-1,3-oxazole 在 盐酸 、 tin(II) chloride dihdyrate 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以57%的产率得到3-chloro-4-(1,3-oxazol-5-yl)aniline
  参考文献：
  名称：

  [EN] NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM
  [FR] NOUVEAUX COMPOSÉS ET LEUR UTILISATION EN TANT QUE SUBSTANCES THÉRAPEUTIQUEMENT ACTIVES DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES IMPLIQUANT L'ÉPITHÉLIUM PIGMENTAIRE RÉTINIEN

  摘要：

  本发明涉及新化合物及其作为治疗活性物质在涉及视网膜色素上皮的疾病的治疗和/或预防中的用途，特别是在涉及导致视网膜色素上皮发生萎缩、退化或死亡的疾病的治疗和/或预防中，这些疾病可能还会导致视网膜色素上皮的萎缩或光感受器的丧失和/或视网膜新生血管生成的治疗和/或预防。

  公开号：

  WO2021257092A1
• 作为产物：
  描述：

  2-氯-4-硝基甲苯 在 盐酸 、 硫酸 、 potassium carbonate 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 5-(2-chloro-4-nitrophenyl)-1,3-oxazole
  参考文献：
  名称：

  Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety

  摘要：

  The first reported structure-activity relationships (SARs) about the N-[3-methoxy-4-(5-oxazolyi)phenyl moiety for a series of recently disclosed inosine monophosphate dehydrogenase (IMPDH) inhibitors are described. The syntheses and in vitro inhibitory values for IMPDH II, and T-cell proliferation (for select analogues) are given. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00258-0

文献信息

• Inhibitors of IMPDH enzyme
  申请人：Vertex Pharmaceuticals, Incorporated

  公开号：US06344465B1

  公开（公告）日：2002-02-05

  The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.

  本发明涉及一类新型的IMPDH抑制剂化合物。该发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制IMPDH酶活性，因此可以优势地用作IMPDH介导的过程的治疗剂。本发明还涉及使用本发明的化合物和相关化合物抑制IMPDH活性的方法。
• [EN] N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES<br/>[FR] DÉRIVÉS DE N-(4-(OXAZOL-5-YL) PHÉNYL)CHROMANE-3-CARBOXAMIDE ET COMPOSÉS APPARENTÉS EN TANT QUE STIMULATEURS DE LA PRODUCTION DE CELLULES PRÉCURSEURS RÉTINIENNES POUR LE TRAITEMENT DE MALADIES NEURORÉTINIENNES
  申请人：ENDOGENA THERAPEUTICS INC

  公开号：WO2020140050A1

  公开（公告）日：2020-07-02

  New compounds and to a method of treating a retinal disease that leads to photoreceptor loss or outer-retina degeneration, comprising administering compound of the formula (I) or a pharmaceutically acceptable salt, a racemic mixture, a corresponding enantiomer or, if applicable, a corresponding diastereomer thereof, wherein: A is a is selected from the group consisting of a 5-oxazolyl, a pyridine-4-yl, a triazolyl, a oxadiazolyl, a imidazolyl and a 2-methyloxazol-5-yl residue, R1, and R12 are independently selected from the group consisting of hydrogen, fluoro, chloro, methoxy, trifluoromethyl, methyl and difluoromethoxy, B is selected from the group consisting of a residue of formula (II), (III), (IV), (V), (VI), (VII), (VIII) and (IX) wherein, II*II denotes the point of attachment to the remainder of the molecule, and R2, R3, R4, R5, R2 I, R3 I, R4 I, R5 I, R2 II, R3 II R4 II, R5 II, R2 III, R3 III, R4 III, R5 III, R2 IV, R3 IV, R4 IV, R5 IV, R2 V, R3 V, R4 V, R5 V , R2 VI, R3 VI, R4 VI, R5 VI,R2 VII, R3 VII, R4 VII, R5 VII, are independently selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 3 carbon atoms, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, 2,2,2-trifluoromethyl and difluoromethoxy.

  新化合物及治疗导致光感受器丧失或外视网膜退化的视网膜疾病的方法，包括给予式(I)的化合物或其药学上可接受的盐、消旋混合物、相应对映体或如适用的话，相应的二对映体，其中：A选自由5-噁唑基、吡啶-4-基、三唑基、噁二唑基、咪唑基和2-甲氧基噁唑-5-基残基的群组，R1和R12独立选自氢、氟、氯、甲氧基、三氟甲基、甲基和二氟甲氧基的群组，B选自式(II)、(III)、(IV)、(V)、(VI)、(VII)、(VIII)和(IX)的残基的群组，其中，II*II表示与分子其余部分的连接点，R2、R3、R4、R5、R2 I、R3 I、R4 I、R5 I、R2 II、R3 II、R4 II、R5 II、R2 III、R3 III、R4 III、R5 III、R2 IV、R3 IV、R4 IV、R5 IV、R2 V、R3 V、R4 V、R5 V、R2 VI、R3 VI、R4 VI、R5 VI、R2 VII、R3 VII、R4 VII、R5 VII独立选自氢、具有1至3个碳原子的直链或支链烷基、氟、氯、溴、甲氧基、乙氧基、丙氧基、2,2,2-三氟甲基和二氟甲氧基的群组。
• Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, novel oxazole compound, and process of preparing the same
  申请人：THE NIPPON SYNTHETIC CHEMICAL INDUSTRY CO., LTD.

  公开号：US20020035265A1

  公开（公告）日：2002-03-21

  A 5-(2-substituted-4-nitrophenyl)-oxazole is prepared by decarboxylating a 5-(2-substituted-4-nitrophenyl)-4-oxazolecarboxylic acid in an aprotic amide solvent containing a protic compound. A 5-(2-substituted-4-nitrophenyl)-oxazolecarboxylic acid and a 5-(2-substituted-4-nitrophenyl)-carboalkoxyoxazole, which are novel compounds, are provided.

  一种5-(2-取代-4-硝基苯基)-噁唑通过在含有质子化合物的无质子酰胺溶剂中脱羧5-(2-取代-4-硝基苯基)-4-噁唑羧酸而制备。同时提供了一种5-(2-取代-4-硝基苯基)-噁唑羧酸和一种5-(2-取代-4-硝基苯基)-碳基氧杂噁唑，它们是新颖的化合物。
• Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, oxazole compound, and process of preparing the same
  申请人：The Nippon Synthetic Chemical Industry Co., Ltd.

  公开号：EP1186598A1

  公开（公告）日：2002-03-13

  A 5-(2-substituted-4-nitrophenyl)-oxazole is prepared by decarboxylating a 5-(2-substituted-4-nitrophenyl)-4-oxazolecarboxylic acid in an aprotic amide solvent containing a protic compound. A 5-(2-substituted-4-nitrophenyl)-oxazolecarboxylic acid and a 5-(2-substituted-4-nitrophenyl)-carboalkoxyoxazole, which are novel compounds, are provided.

  一种 5-(2-取代-4-硝基苯基)-噁唑是通过在含有一种原生化合物的烷基酰胺溶剂中对一种 5-(2-取代-4-硝基苯基)-4-噁唑羧酸进行脱羧而制备的。本发明提供了一种 5-(2-取代-4-硝基苯基)-噁唑羧酸和一种 5-(2-取代-4-硝基苯基)-羧基噁唑，它们都是新型化合物。
• Compounds for use as therapeutically active substances in the treatment of retinal diseases
  申请人：ENDOGENA THERAPEUTICS, INC.

  公开号：US10752593B2

  公开（公告）日：2020-08-25

  A method of treating a retinal disease that leads to photoreceptor loss or outer-retina degeneration, includes administering a compound of formula (Ia) or a pharmaceutically acceptable salt thereof to a patient having the retinal disease so as to be delivered to an eye of the patient in an amount effective to treat the retinal disease: wherein A is an 5-oxazolyl residue or a pyridine-4-yl residue, R1 is selected from the group consisting of methoxy, fluoro and chloro; R2, R3, R4, R5 and R6 of the phenyl ring B are independently from each other selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 4 carbon atoms, trifluoromethyl, 2,2,2-trifluoroethyl, methylsulfanyl, ethylsulfanyl, methylsulfonyl, ethylsulfonyl, difluoromethoxy, trifluoromethoxy, fluoro, bromo, chloro, methoxy, ethoxy, propoxy, butoxy, hydroxy and amino; and at least two of R2, R3, R4, R5 and R6 are hydrogens.

  一种治疗导致光感受器缺失或外视网膜变性的视网膜疾病的方法，包括向患有视网膜疾病的患者施用式（Ia）化合物或其药学上可接受的盐，以便以有效治疗视网膜疾病的量输送到患者的眼睛中： 其中 A 是 5-恶唑基残基或吡啶-4-基残基，R1 选自甲氧基、氟和氯组成的组；苯基环 B 的 R2、R3、R4、R5 和 R6 相互独立地选自氢、具有 1 至 4 个碳原子的直链或支链烷基、三氟甲基、2,2,2-三氟乙基、甲硫基、乙硫基、甲磺酰基、乙磺酰基、二氟甲氧基、三氟甲氧基、氟、溴、氯、甲氧基、乙氧基、丙氧基、丁氧基、羟基和氨基组成的组；R2、R3、R4、R5 和 R6 中至少有两个是氢。